Comment on "Levothyrox^® New and Old Formulations: Are they Switchable for Millions of Patients?"

Clin Pharmacokinet. 2020 Feb;59(2):281-282. doi: 10.1007/s40262-019-00850-5.

Authors

Yang Yu^{1

2}, Marc Maliepaard^{3

4}

Affiliations

¹ Medicines Evaluation Board, Utrecht, The Netherlands. [email protected].
² Department of Pharmacology and Toxicology, Radboud University Medical Centre, Nijmegen, The Netherlands. [email protected].
³ Medicines Evaluation Board, Utrecht, The Netherlands.
⁴ Department of Pharmacology and Toxicology, Radboud University Medical Centre, Nijmegen, The Netherlands.

PMID: 31802403
DOI: 10.1007/s40262-019-00850-5

No abstract available

Publication types

Letter
Comment

MeSH terms

Drug Compounding
Humans
Thyroxine*

Substances

Thyroxine